Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-ECL1i PET in Atherosclerosis
NCT04537403Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2020
- Primary completion
- Sep 2025
- Modality
- Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label trial of Cu-DOTA-ECL1i in carotid atheroma (CAS) and peripheral arterial disease (PAD) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Evaluation of 64CU-ECL1i imaging characteristics. Started Oct 2020; status: recruiting.
02
Drugs
Cu-DOTA-ECL1i
03
Conditions
carotid atheroma (CAS)peripheral arterial disease (PAD)
Beyond the preview
Go deeper on NCT04537403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537403.